查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1832514

細胞治療市場按類型、治療類型、給藥方法、應用和最終用戶分類—2025-2032 年全球預測

Cell Therapy Market by Type, Therapy Type, Mode of Administration, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年細胞治療市場規模將成長至 225 億美元，複合年成長率為 11.22%。

主要市場統計數據
基準年2024年 96億美元
預計2025年 106.4億美元
預測年份：2032年 225億美元
複合年成長率（%） 11.22%

細胞療法已成為現代生物醫學領域最具活力的前沿領域之一，透過融合先進的細胞工程、免疫學和再生方法，滿足尚未滿足的臨床需求。近年來，科學進展已從概念驗證研究轉向日益複雜的臨床項目，涵蓋自體和同種異體構建體、多樣化的給藥方法以及更廣泛的治療應用。隨著技術堆疊的成熟，相關人員如今面臨著科學、監管、製造和商業性力量的複雜相互作用，這些力量將決定轉化療法的成功。

本導言透過強調將影響專案進度和商業性準備的策略曲折點，幫助讀者置身於這種複雜環境中。本書強調了平台標準化、模組化製造和付款人參與等趨同趨勢，這些趨勢推動著開發商、服務供應商和臨床機構的決策。重要的是，本書的視角超越了實驗室，涵蓋了現實世界的實施挑戰，包括供應鏈彈性、載體生產和病患獲取途徑。本章從商業視角審視這一形勢，幫助領導者評估投資重點、如何降低風險，以及哪些夥伴關係能夠加速從臨床前景到永續治療交付的轉變。

由於技術突破、監管演變、製造進步和付款人參與動態，細胞治療領域正在發生重大變化。

近年來，細胞治療領域經歷了重大變革，這既得益於技術突破，也得益於患者治療方式的系統性轉變。基因編輯和模組化製造方法減少了技術瓶頸，並實現了治療結構的迭代改進。同時，監管機構也採用了適應性證據框架，改變了研發時間表，並為有條件的市場准入開闢了新的途徑。總的來說，這些變化加速了學習週期，並使得從早期臨床試驗到更廣泛的臨床計畫的過渡更快。

同時，隨著支付方和醫療保健提供者日益重視現實世界的結果和長期價值，商業化動態也隨之演變。這種轉變迫使申辦方設計超越隨機對照試驗的證據策略，涵蓋註冊庫、實用性試驗和健康經濟模型。製造業也正在經歷結構性轉變，為了應對物流複雜性和區域准入挑戰，分散式和混合式製造模式越來越受到青睞。總體而言，這些轉型變革為開發商、製造外包、臨床中心和支付方之間的合作創造了新的機遇，並要求制定能夠平衡科學抱負和營運擴充性的適應性策略。

2025年美國關稅變化對細胞治療供應鏈的累積影響：跨境採購組件的定價和策略採購考量

美國將於2025年實施關稅改革，將對細胞療法供應鏈、採購決策和跨國籌資策略產生連鎖影響。儘管細胞療法研發的許多環節依賴全球採購的專用試劑、耗材和設備，但關稅已經改變了供應商的相對經濟效益，促使專案團隊重新評估其供應商組合。因此，籌資策略正轉向地域多元化、更深入地評估替代供應商的資格以及規避單一來源的風險。

應對關稅成本壓力的措施包括重新協商供應商合約、延長關鍵原料的庫存前置作業時間，以及盡可能加快上游工程的本地化。生產規劃人員評估了集中式大批量生產與規模較小、區域化生產基地之間的利弊，這些基地可以降低關稅和物流的脆弱性。同時，臨床實驗試驗管理人員也調整了選址標準，以應對潛在的關稅延遲和試劑供應問題，從而影響試驗計劃和患者入組速度。這些累積影響凸顯了動態供應鏈管治、情境規劃和積極主動的監管參與的必要性，以便在對外貿易政策發生變化的情況下，保持計畫的連續性和臨床計畫的順利進行。

關鍵市場細分洞察揭示了治療類型、給藥途徑、臨床用途、地理來源和最終用戶如何決定開發平臺和市場發展

透過細分市場分析，我們發現不同的發展路徑和臨床用例​​需要不同的策略方法。非幹細胞類別包括CAR-T細胞、樹突狀細胞和自然殺手細胞項目，每個項目都有各自的生產足跡和臨床終點。同時，幹細胞類別包括胚胎幹細胞、造血幹細胞和間質幹細胞，每個項目都有不同的倫理、監管和規模化考量。根據治療方法來源，項目分為同種異體和自體，自體療法需要個人化的供應鏈和患者材料物流，而同種異體療法則強調大量生產和細胞庫的持久性。

肌肉注射、腫瘤內注射和靜脈注射有不同的臨床工作流程、安全監測和製劑穩定性要求。自體免疫疾病（例如多發性硬化症和類風濕性關節炎）需要慢性治療模式和長期安全監測，而骨髓惡性腫瘤和固態腫瘤的腫瘤學治療方案也有所不同，具有不同的腫瘤微環境挑戰和反應指標。感染疾病的應用涵蓋細菌和病毒感染，具有不同的急性治療時間表和監管終點。最後，最終用戶（包括學術和研究機構、診所、商業實驗室和醫院）在不同的採購、基礎設施和報銷環境中營運，這會影響採用速度和核准後支援模式。整合這些細分市場可以使開發策略與臨床、營運和商業現實更加準確地保持一致。

美洲、中東和非洲以及亞太地區的區域動態和戰略考量影響製造地和臨床試驗中心的准入

區域動態對專案設計、生產策略和市場進入規劃有著強大的影響，美洲、歐洲、中東和非洲以及亞太地區呈現出明顯的區域動態。在美洲，卓越的臨床中心和強大的投資生態系統推動先進的臨床項目和大規模生產舉措，而監管機構則強調安全性和上市後證據。在歐洲、中東和非洲，跨多個司法管轄區的監管協調和強大的臨床網路正在塑造跨國臨床試驗設計和聯合生產夥伴關係，但各國的報銷框架差異很大，可能會影響上市順序。

亞太地區擁有多元化的臨床和生產能力，多個國家正在成為早期臨床開發和受託製造的區域中心。一些市場的監管現代化正在加速本地臨床試驗的發展。在每個地區，臨床基礎設施、人才和本地生產獎勵相互作用，推動著關於場地位置和臨床試驗執行的決策。此外，隨著相關人員尋求在韌性與成本效益和病患可及性需求之間取得平衡，跨境合作、技術轉移協議和區域供應路線也在不斷發展。

對細胞治療生態系統中的主要企業進行審查，重點關注競爭定位、合作模式、平台專業化和競爭差異化策略

細胞療法生態系統中的主要企業展現出差異化策略，體現了其核心競爭力和長遠目標。大型製藥企業通常會透過平台收購或策略聯盟，將細胞療法能力整合到其更廣泛的免疫腫瘤學或再生醫學產品組合中，並利用其商業基礎設施來擴大其後期產品線。純細胞療法開發者往往專注於科學差異化，例如新穎的工程構建體或獨特的細胞表現型，優先考慮轉化概念驗證和臨床差異化，以確保獲得夥伴關係和許可協議。

製造和技術服務提供者強調可擴展性、品質系統和供應鏈可靠性，將自己定位為缺乏內部製造能力的公司的必要推動者。工具和試劑供應商正憑藉專有技術、自動化解決方案和檢驗的耗材來降低製程差異，從而實現差異化。學術衍生公司和研究機構繼續發揮創新來源的作用，將基礎發現轉化為早期臨床計畫。在所有這些相關人員中，從共同開發夥伴關係到按服務收費安排等各種合作模式正在塑造能力的整合方式。競爭差異化日益取決於可重複製造、滿足監管要求以及在核准後產生可靠真實世界證據的能力。

為行業領導者提供切實可行的建議，以加速翻譯，最佳化供應鏈，加強監管參與，並確保永續的商業性發展道路。

產業領導者應採取一系列切實可行的舉措，在短期實用性與長期策略定位之間取得平衡。首先，透過設計能夠同時產生監管和付款人相關終點的試驗，將研發重點與可操作證據的生成結合。其次，透過識別二級供應商、制定區域籌資策略以及考慮混合製造佈局來投資供應鏈韌性，以減輕關稅和物流脆弱性的影響。

研發領導者還必須優先考慮早期和持續的監管參與，利用科學建議和靈活的監管途徑，降低關鍵研發步驟的風險，並明確核准後證據的前景。他們必須積極尋求策略夥伴關係，與製造外包、臨床網路和技術供應商合作，以加速產能擴張，同時保持資本效率。他們還必須將衛生經濟學和療效研究納入研發計劃，以向付款人和醫療保健系統證明其價值。最後，他們必須透過投資自動化、數位身分共同追蹤和員工發展項目來促進卓越營運，以減少差異性，並加快自體和異體計畫的患者獲準時間。

調查方法與證據綜合 資料來源描述 專家諮詢分析法 用於建構分析的架構與檢驗過程

調查方法將結構化證據整合與初步質性研究相結合，以提供穩健且檢驗的分析。此方法首先全面回顧已發表的科學文獻、監管指南文件、臨床試驗註冊和專利態勢，以深入了解該平台技術及其臨床發展軌跡。隨後，研究提出了關鍵的主題假設，並透過專家諮詢檢驗，包括採訪臨床實驗人員、生產主管、研究人員和監管專家，提供營運背景和未來展望。

所採用的分析架構包括：供應鏈圖譜識別瓶頸、細分分析使專案策略與臨床用例保持一致，以及情境規劃評估政策和貿易影響。研究結果透過證據來源三角最後覆核，並在與領域專家的研討會上檢驗，以確保實踐相關性並完善建議。在整個過程中，我們強調假設的透明度、證據的可追溯性以及結合相關人員回饋的迭代檢驗循環，以提高洞察的準確性和適用性。

結論總結，重點強調了相關人員在細胞治療中最大化臨床和商業性影響的策略要務、持續挑戰和實際途徑

結論簡潔地總結了該分析，並將其作為整個細胞治療生態系統相關人員的策略要務。儘管科學發展勢頭持續擴大潛在的治療成分，但商業性成功越來越依賴製造、供應鏈和付款人參與的卓越營運。將科學差異化與可重複、擴充性的流程以及早期價值展示相結合的組織，將能夠更好地滿足監管期望並確保持續的市場進入。持續存在的挑戰，例如自體治療物流、製造差異性和區域監管碎片化，需要一種協調一致的應對策略，將公私合作與有針對性的投資相結合。

展望未來，生態系統將獎勵那些適應性強的組織，這些組織採用模組化生產模式，投資於用於身分和結果追蹤的數位基礎設施，並積極與付款方合作，設計反映實際績效的證據包。將這些策略重點與嚴格的執行相結合，將使相關人員能夠加快患者可及性，同時管理先進細胞療法固有的營運複雜性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 標準化劑量和縮短製造時間將使現成的同種異體CAR-T 療法迅速出現
  • 整合自動化封閉回路型生物反應器系統，實現可擴展的生產和品管
  • 應用 CRISPR 基因編輯技術設計出具有增強腫瘤特異性的下一代通用供體 T 細胞
  • 引入分散式 POC 製造，以簡化自體細胞療法向遠距治療中心的交付
  • 引入人工智慧主導的分析，用於即時效力評估和細胞治療釋放標準的最佳化
  • 透過調節腫瘤微環境的策略將細胞治療應用擴展到固態腫瘤
  • 開發將細胞療法與免疫查核點抑制劑結合的聯合治療，以提高持久緩解率
  • 建立全球監管協調框架，加速細胞療法的臨床應用和市場核准

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章細胞治療市場（按類型）

  • 非幹細胞
    • CAR-T細胞
    • 樹突狀細胞
    • NK細胞
  • 幹細胞
    • 胚胎幹細胞
    • 造血幹細胞
    • 間質幹細胞

第9章 細胞治療市場（依治療類型）

  • 同種
  • 自體移植

第 10 章 細胞治療市場（依給藥方法）

  • 肌肉注射
  • 腫瘤內
  • 靜脈

第 11 章細胞治療市場：依應用

  • 自體免疫疾病
    • 多發性硬化症
    • 類風濕性關節炎
  • 癌症治療
    • 造血系統惡性腫瘤
    • 固態腫瘤
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染
  • 再生醫學

第 12 章 細胞治療市場（依最終使用者）

  • 學術研究機構
  • 診所
  • 商業實驗室
  • 醫院

第13章 細胞治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章細胞治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國細胞治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Anterogen Co., Ltd.
    • Astellas Pharma Inc.
    • Athersys, Inc.
    • BioNTech SE
    • Bristol-Myers Squibb Company
    • Castle Creek Biosciences, Inc.
    • Catalent, Inc.
    • FUJIFILM Holdings Corporation
    • Gilead Sciences, Inc.
    • JCR Pharmaceuticals Co., Ltd.
    • Kolon TissueGene, Inc.
    • Lonza Group Ltd.
    • Medipost Co., Ltd.
    • Mesoblast Ltd.
    • Novartis AG
    • NuVasive, Inc.
    • Pfizer Inc.
    • Sartorius AG
    • Stemedica Cell Technologies, Inc.
    • Stempeutics Research Pvt. Ltd.
    • Takeda Pharmaceutical Company Limited
    • TegoScience
    • Thermo Fisher Scientific, Inc.
    • Vericel Corporation
Product Code: MRR-433AB1DC28D4

The Cell Therapy Market is projected to grow by USD 22.50 billion at a CAGR of 11.22% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.60 billion
Estimated Year [2025] USD 10.64 billion
Forecast Year [2032] USD 22.50 billion
CAGR (%) 11.22%

Cell therapy has emerged as one of the most dynamic frontiers in modern biomedicine, blending advanced cellular engineering, immunology, and regenerative approaches to address unmet clinical needs. Over recent years, scientific progress has migrated from conceptual proof-of-concept work into increasingly sophisticated clinical programs that span autologous and allogenic constructs, diverse modes of administration, and a widening set of therapeutic applications. As the technology stack matures, stakeholders now confront a complex interplay of scientific, regulatory, manufacturing, and commercial forces that shape translational success.

This introduction situates readers within that complexity by focusing on the strategic inflection points that influence program progression and commercial readiness. It emphasizes the convergent trends-platform standardization, modular manufacturing, and payer engagement-that drive decision-making across developers, service providers, and clinical institutions. Importantly, the narrative moves beyond the laboratory to consider real-world implementation challenges, including supply chain resilience, vector production, and patient access pathways. By framing the landscape in operational terms, the section prepares leaders to assess where to concentrate investment, how to mitigate risk, and which partnerships accelerate movement from clinical promise to sustainable therapeutic delivery.

Transformative shifts reshaping the cell therapy landscape driven by technological breakthroughs regulatory evolution manufacturing advances and payer engagement dynamics

Recent years have produced transformative shifts across the cell therapy landscape, driven by both technological breakthroughs and systemic changes in how therapies progress to patients. Gene editing and modular manufacturing approaches have reduced technical bottlenecks and enabled iterative refinement of therapeutic constructs. In parallel, regulatory agencies have signaled greater willingness to engage in adaptive evidence frameworks, which has altered development timelines and opened new pathways for conditional market access. These changes collectively accelerate learning cycles and enable faster translation from early clinical studies into broader clinical programs.

Concurrently, commercialization dynamics have evolved as payers and providers emphasize real-world outcomes and long-term value. This shift compels sponsors to design evidence strategies that extend beyond randomized controlled trials to include registries, pragmatic studies, and health economic models. Manufacturing has also experienced a structural pivot: decentralized and hybrid production models are gaining traction as a response to logistical complexity and regional access challenges. Altogether, these transformative shifts create new opportunities for collaboration between developers, contract manufacturers, clinical centers, and payers, and they demand adaptive strategies that balance scientific ambition with operational scalability.

Cumulative implications of United States tariff changes in 2025 on cell therapy supply chains cross-border sourcing component pricing and strategic procurement considerations

The introduction of tariff changes in the United States in 2025 has exerted a cascading influence on cell therapy supply chains, procurement decisions, and cross-border sourcing strategies. While many components of cell therapy development depend on specialized reagents, disposables, and instrumentation sourced globally, tariffs have altered relative supplier economics and prompted program teams to reassess supplier portfolios. As a result, procurement strategies have shifted toward increased geographic diversification and deeper qualification of alternative suppliers to hedge against single-source exposure.

Operational responses to tariff-induced cost pressures include renegotiating supplier contracts, extending inventory lead times for critical materials, and accelerating localization of upstream activities where feasible. Manufacturing planners have evaluated the trade-off between centralized high-volume production versus regionalized, smaller-scale facilities that reduce tariff and logistics vulnerability. In parallel, clinical trial managers have adapted site selection criteria to factor in potential customs delays and reagent availability, which affects scheduling and patient enrollment pacing. These cumulative effects underscore the need for dynamic supply-chain governance, scenario planning, and proactive regulatory engagement to maintain program continuity and preserve clinical timelines despite external trade policy shifts.

Key segmentation insights revealing how therapeutic type administration route clinical application therapy origin and end users define development pipelines and market access

Deconstructing the market through segmentation reveals how different development pathways and clinical use cases necessitate distinct strategic approaches. When examined by type, the landscape is split between Non-stem Cells and Stem Cells; the Non-stem Cells category prominently includes CAR-T cells, dendritic cells, and natural killer cell programs, each with unique manufacturing footprints and clinical endpoints, while the Stem Cells category comprises embryonic stem cells, hematopoietic stem cells, and mesenchymal stem cells, which raise distinct ethical, regulatory, and scale-up considerations. Based on therapy origin, programs cluster into allogenic and autologous modalities, where autologous approaches require personalized supply chains and patient material logistics and allogenic approaches emphasize batch manufacturing and durability of cell banks.

Administration routes further differentiate development and adoption strategies: intramuscular, intratumoral, and intravenous deliveries impose varied clinical workflows, safety monitoring, and formulation stability requirements. Application-driven segmentation highlights pathway-specific needs: autoimmune disorders-such as multiple sclerosis and rheumatoid arthritis-demand chronic treatment models and long-term safety surveillance, whereas cancer treatment programs diverge between hematologic malignancies and solid tumors with corresponding differences in tumor microenvironment challenges and response metrics. Infectious disease applications span bacterial and viral infections with acute treatment timelines and distinct regulatory endpoints. Finally, end users including academic and research institutes, clinics, commercial laboratories, and hospitals each operate within different procurement, infrastructure, and reimbursement environments, which influences adoption speed and post-approval support models. Integrating these segmentation lenses enables more precise alignment of development strategies with clinical, operational, and commercial realities.

Regional dynamics and strategic considerations across Americas Europe Middle East & Africa and Asia-Pacific that influence clinical trial hubs manufacturing sites and access

Regional dynamics exert a powerful influence on program design, manufacturing strategy, and market access planning, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, centers of clinical excellence and a robust investment ecosystem drive advanced clinical programs and large-scale manufacturing initiatives, while regulatory pathways emphasize safety and post-market evidence commitments. In Europe, Middle East & Africa, regulatory harmonization across multiple jurisdictions and strong clinical networks shape multinational trial designs and collaborative manufacturing partnerships, although country-level reimbursement frameworks can vary significantly and influence launch sequencing.

Asia-Pacific presents a diverse range of clinical competencies and manufacturing capabilities, with several countries emerging as regional hubs for both early clinical development and contract manufacturing services; favorable regulatory modernization in some markets has accelerated local trial activity. Across all regions, the interplay between clinical infrastructure, talent availability, and local manufacturing incentives informs decisions on facility placement and trial execution. Moreover, cross-border collaborations, technology transfer agreements, and regional supply routes continue to evolve as stakeholders seek to balance resilience with cost efficiency and patient access imperatives.

Key company insights spotlighting competitive positioning collaboration models platform specialization and competitive differentiation strategies within cell therapy ecosystems

Key companies operating across the cell therapy ecosystem exhibit differentiated strategies that reflect their core capabilities and long-term ambitions. Large pharmaceutical firms often pursue platform acquisition and strategic partnerships to integrate cell therapy capabilities into broader immuno-oncology and regenerative portfolios, leveraging their commercial infrastructure to scale later-stage products. Pure-play cell therapy developers tend to focus on scientific differentiation-such as novel engineering constructs or unique cell phenotypes-and they prioritize translational proof and clinical differentiation to attract partnerships or licensing deals.

Providers of manufacturing and technical services emphasize scalability, quality systems, and supply-chain reliability, positioning themselves as essential enablers for companies that lack in-house production capacity. Tool and reagent suppliers differentiate through proprietary technologies, automation solutions, and validated consumables that reduce process variability. Academic spinouts and research institutes continue to serve as innovation sources, translating basic discoveries into early clinical programs. Across all these actors, collaboration models-ranging from co-development partnerships to fee-for-service arrangements-shape how capabilities are combined. Competitive differentiation increasingly hinges on demonstrated manufacturing reproducibility, regulatory readiness, and the ability to generate robust real-world evidence post-approval.

Actionable recommendations for industry leaders to accelerate translation optimize supply chains enhance regulatory engagement and secure sustainable commercial pathways

Industry leaders should pursue a set of pragmatic, actionable moves that balance near-term operability with long-term strategic positioning. First, align R&D priorities with pragmatic evidence generation by designing trials that produce both regulatory and payer-relevant endpoints; this dual focus accelerates market access discussions and reduces downstream negotiation risk. Next, invest in supply-chain resilience by qualifying secondary suppliers, developing regional sourcing strategies, and examining hybrid manufacturing footprints that reduce tariff exposure and logistical vulnerability.

Leaders must also prioritize regulatory engagement early and continuously, leveraging scientific advice and adaptive regulatory pathways to de-risk pivotal development steps and to clarify post-approval evidence commitments. Strategic partnerships merit active pursuit: form alliances with contract manufacturers, clinical networks, and technology providers to accelerate capacity build-out while preserving capital efficiency. Additionally, embed health economics and outcomes research into development plans to demonstrate value to payers and health systems; early modeling and real-world data capture will inform pricing and reimbursement strategies. Finally, cultivate operational excellence through investment in automation, digital tracking of chain-of-identity, and workforce training programs that reduce variability and accelerate time-to-patient across both autologous and allogenic programs.

Research methodology and evidence synthesis explaining data sources expert consultation methods analytical frameworks and validation processes used to build the analysis

The research methodology combines a structured evidence synthesis with primary qualitative engagement to deliver a robust, validated analysis. The approach began with a comprehensive review of publicly available scientific literature, regulatory guidance documents, clinical trial registries, and patent landscapes to develop a foundational understanding of platform technologies and clinical trajectories. This secondary research established key thematic hypotheses that were then tested through targeted expert consultations, including interviews with developers, manufacturing executives, clinical investigators, and regulatory specialists to obtain operational context and forward-looking perspectives.

Analytical frameworks employed include supply-chain mapping to identify chokepoints, segmentation analysis to align program strategy with clinical use cases, and scenario planning to assess policy and trade impacts. Findings were cross-checked through triangulation of evidence sources and validated in workshops with subject-matter experts to ensure practical relevance and to refine recommendations. Throughout, the process emphasized transparency of assumptions, traceability of evidence, and an iterative validation loop that incorporated stakeholder feedback to improve accuracy and applicability of the insights.

Concluding synthesis highlighting strategic imperatives persistent challenges and pragmatic pathways for stakeholders to maximize clinical and commercial impact in cell therapy

The conclusion synthesizes the analysis into a concise set of strategic imperatives for stakeholders across the cell therapy ecosystem. Scientific momentum continues to expand the range of viable therapeutic constructs, yet commercial success increasingly depends on operational excellence across manufacturing, supply chain, and payer engagement. Organizations that couple scientific differentiation with reproducible, scalable processes and early value demonstration will be better positioned to navigate regulatory expectations and secure durable market access. Persistent challenges-such as logistics for autologous therapies, manufacturing variability, and regional regulatory fragmentation-require coordinated response strategies that blend public-private collaboration with targeted investments.

Looking ahead, the ecosystem will reward adaptive organizations that embrace modular production models, invest in digital infrastructure for chain-of-identity and outcomes capture, and proactively engage payers to design evidence packages that reflect real-world performance. By integrating these strategic priorities with disciplined execution, stakeholders can accelerate patient access while managing the operational complexities inherent to advanced cell-based therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid emergence of allogeneic off-the-shelf CAR-T therapies with standardized dosing and reduced manufacturing timelines
  • 5.2. Integration of automated closed-loop bioreactor systems for scalable cell therapy production and quality control
  • 5.3. Application of CRISPR gene editing to engineer next generation universal donor T cells with enhanced tumor specificity
  • 5.4. Implementation of decentralized point-of-care manufacturing to streamline autologous cell therapy delivery to remote treatment centers
  • 5.5. Adoption of artificial intelligence-driven analytics for real-time potency assessment and release criteria optimization in cell therapies
  • 5.6. Expansion of cell therapy indications into solid tumor treatments through tumor microenvironment modulation strategies
  • 5.7. Development of combination regimens combining cell therapies with immune checkpoint inhibitors to improve durable response rates
  • 5.8. Establishment of global regulatory harmonization frameworks to accelerate clinical adoption and market authorization of cell treatments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell Therapy Market, by Type

  • 8.1. Non-stem Cells
    • 8.1.1. CAR-T Cells
    • 8.1.2. Dendritic Cells
    • 8.1.3. NK Cells
  • 8.2. Stem Cells
    • 8.2.1. Embryonic Stem Cells
    • 8.2.2. Hematopoietic Stem Cell
    • 8.2.3. Mesenchymal Stem Cell

9. Cell Therapy Market, by Therapy Type

  • 9.1. Allogenic
  • 9.2. Autologous

10. Cell Therapy Market, by Mode of Administration

  • 10.1. Intramuscular
  • 10.2. Intratumoral
  • 10.3. Intravenous

11. Cell Therapy Market, by Application

  • 11.1. Autoimmune Disorders
    • 11.1.1. Multiple Sclerosis
    • 11.1.2. Rheumatoid Arthritis
  • 11.2. Cancer Treatment
    • 11.2.1. Hematologic Malignancies
    • 11.2.2. Solid Tumors
  • 11.3. Infectious Diseases
    • 11.3.1. Bacterial Infections
    • 11.3.2. Viral Infections
  • 11.4. Regenerative Medicine

12. Cell Therapy Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Clinics
  • 12.3. Commercial Laboratories
  • 12.4. Hospitals

13. Cell Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Anterogen Co., Ltd.
    • 16.3.2. Astellas Pharma Inc.
    • 16.3.3. Athersys, Inc.
    • 16.3.4. BioNTech SE
    • 16.3.5. Bristol-Myers Squibb Company
    • 16.3.6. Castle Creek Biosciences, Inc.
    • 16.3.7. Catalent, Inc.
    • 16.3.8. FUJIFILM Holdings Corporation
    • 16.3.9. Gilead Sciences, Inc.
    • 16.3.10. JCR Pharmaceuticals Co., Ltd.
    • 16.3.11. Kolon TissueGene, Inc.
    • 16.3.12. Lonza Group Ltd.
    • 16.3.13. Medipost Co., Ltd.
    • 16.3.14. Mesoblast Ltd.
    • 16.3.15. Novartis AG
    • 16.3.16. NuVasive, Inc.
    • 16.3.17. Pfizer Inc.
    • 16.3.18. Sartorius AG
    • 16.3.19. Stemedica Cell Technologies, Inc.
    • 16.3.20. Stempeutics Research Pvt. Ltd.
    • 16.3.21. Takeda Pharmaceutical Company Limited
    • 16.3.22. TegoScience
    • 16.3.23. Thermo Fisher Scientific, Inc.
    • 16.3.24. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CELL THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELL THERAPY MARKET SIZE, BY CAR-T CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELL THERAPY MARKET SIZE, BY DENDRITIC CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELL THERAPY MARKET SIZE, BY NK CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELL THERAPY MARKET SIZE, BY STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELL THERAPY MARKET SIZE, BY ALLOGENIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELL THERAPY MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELL THERAPY MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELL THERAPY MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELL THERAPY MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELL THERAPY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CELL THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CELL THERAPY MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CELL THERAPY MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST CELL THERAPY MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. AFRICA CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 326. AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 329. AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 332. AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 333. AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 334. AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 335. AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 336. AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 337. AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 338. AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 339. AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 340. AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 341. AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 343. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)